This inventor holds 5 USPTO granted patents, plus 2 CIPO patents and 2 EPO patents. Top assignees: Johns Hopkins University, Leland Stanford Junior University, Allosteros Therapeutics, Inc.. Active years: 2003-2022.
Company Filing History:
2 out of 3,790 
2 out of 5,489 
1 out of 1 Years Active: 2003-2022
Title: Howard Schulman: Innovator in CaMKII Inhibitors
Introduction
Howard Schulman is a notable inventor based in Palo Alto, CA (US). He has made significant contributions to the field of biochemistry, particularly in the development of compounds that inhibit Ca/calmodulin-dependent protein kinase (CaMKII). With a total of 5 patents, Schulman's work has the potential to impact various therapeutic applications.
Latest Patents
Schulman's latest patents focus on CaMKII inhibitors and their uses. The present invention provides compounds useful as inhibitors of Ca/calmodulin-dependent protein kinase (CaMKII), compositions thereof, and methods of using the same. This innovative approach could lead to advancements in treating conditions related to CaMKII activity.
Career Highlights
Throughout his career, Howard Schulman has worked with prestigious institutions such as Leland Stanford Junior University and The Johns Hopkins University. His research has contributed to a deeper understanding of protein kinases and their role in cellular processes.
Collaborations
Some of Schulman's notable coworkers include Daniel Emil Levy and Bheema Rao Paraselli. Their collaborative efforts have furthered research in the field and enhanced the development of innovative solutions.
Conclusion
Howard Schulman's contributions to the field of biochemistry, particularly through his patents on CaMKII inhibitors, highlight his role as a significant inventor. His work continues to pave the way for future innovations in therapeutic applications.